Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Trial in Dry Eye

 

• Reproxalap Statistically Superior to Vehicle for Both Prespecified Primary Endpoints of Schirmer Test (p=0.0001) and ≥10 mm Schirmer Test Responder Proportions (p<0.0001)
• TRANQUILITY-2 Results May Allow for the Most Comprehensive Dry Eye Disease New Drug Application (NDA) Submission to Date
• Pending Pre-NDA Meeting with the U.S. Food and Drug Administration (FDA), Clinical Efficacy Trials of Reproxalap Believed to Be Complete
• Company to Host Conference Call at 8:00 a.m. ET Today

Aldeyra will host a conference call to discuss this announcement at 8:00 a.m. ET today, June 8, 2022. The dial-in numbers are (844) 200-6205 for domestic callers and (929) 526-1599 for international callers. The access code is 879247. A live webcast of the conference call will also be available on the “Investors & Media” section of the Aldeyra website at https://ir.aldeyra.com. Presentation slides, which contain material information and should be reviewed in conjunction with this press release, will be available on the investor relations page prior to the start of the conference call and webcast.

After the live webcast, the event will remain archived on the Aldeyra website for 90 days.

https://www.biospace.com/article/releases/aldeyra-therapeutics-achieves-primary-endpoint-in-phase-3-tranquility-2-trial-in-dry-eye-disease-and-intends-to-submit-new-drug-application-for-symptoms-and-three-sign-endpoints-of-dry-eye-disease/